Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCHOpen Access

Comparison of Antimicrobial Activity between Ceftriaxone-Sulbactam-Disodium EDTA and Ceftazidime-Avibactam against Carbapenemase Producing Enterobacterales Isolates from a Tertiary Care Hospital: An In-vitro Study

View Full Paper
Ask AI
Bookmark
Share

Authors

RSR. SuriyaLVLeela Kakithakara VajraveluGAG. Anusha

Discussion

Loading...

Member takes

Overview

In-vitro study of CSE and CZA shows 100% efficacy against MBL-producing isolates, indicating important treatment options.

Key Points

  • Ceftriaxone-sulbactam exhibited 100% susceptibility against carbapenemase producers in vitro.
  • Of 39 identified carbapenemase-producing isolates, only 9 showed susceptibility to ceftazidime-avibactam.
  • The study used phenotypic differentiation through modified carbapenem inactivation method and Kirby-Bauer testing.
  • Ceftriaxone-sulbactam may serve as a critical carbapenem-sparing option for treating MBL-producing infections.

Cite This Study

Suriya et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d64791ba0https://doi.org/10.7860/jcdr/2025/79032.21332
View Full Paper
Ask AI
Bookmark
Share